{"id":2895,"date":"2026-08-25T13:09:23","date_gmt":"2026-08-25T12:09:23","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=2895"},"modified":"2026-08-25T13:09:23","modified_gmt":"2026-08-25T12:09:23","slug":"buy-mod-grf-1-29-ipamorelin-blend-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-mod-grf-1-29-ipamorelin-blend-in-switzerland\/","title":{"rendered":"Mod GRF 1-29 & Ipamorelin Blend (10MG)"},"content":{"rendered":"

What Is the Mod GRF 1-29 & Ipamorelin Blend and Why Buy It for Research?<\/strong><\/h2>\n

Buy Mod GRF 1-29 & Ipamorelin Blend in Switzerland for research into growth hormone axis signaling, synergistic GH release, and selective receptor pharmacology. Specifically, this 10mg research formulation combines two complementary growth hormone secretagogues in a single pre-mixed lyophilized vial: Mod GRF 1-29 (CJC-1295 without DAC, 5mg) and Ipamorelin (5mg). This blend pairs a growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue (GHS) to probe convergent pathways in the GH-IGF-1 axis.<\/p>\n

Mod GRF 1-29 (without DAC, also known as CJC-1295 without DAC or Modified GRF 1-29) is a synthetic 29-amino acid peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that engages the GHS-R1a receptor through Gq\/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. Importantly, Ipamorelin is uniquely selective in its action\u2014it stimulates GH release with negligible cortisol or prolactin elevation. When combined, these two peptides produce synergistic GH release\u2014significantly higher than either compound alone. Furthermore, Core Peptides supplies this blend as a lyophilized powder in a 10mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy Mod GRF 1-29 & Ipamorelin Blend in Switzerland.<\/p>\n

Mod GRF 1-29 & Ipamorelin Blend Research Overview: Buy Mod GRF 1-29 & Ipamorelin Blend in Switzerland for GH Axis Studies<\/strong><\/h2>\n

Centrally, research into the Mod GRF 1-29 and Ipamorelin blend has focused on the complementary and synergistic mechanisms of its two components. Researchers established the foundational observation that GHRH + GHRP produces synergistic GH release in human subjects, demonstrating that co-administration of GHRH and GHRP produced GH peaks significantly higher than either peptide alone.<\/p>\n

Mod GRF 1-29 functions as a GHRH analog that binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor (GPCR) on pituitary somatotrophs. The peptide incorporates four strategic amino acid substitutions at positions 2 (Ala to D-Ala), 8 (Asn to Gln), 15 (Gly to Ala), and 27 (Met to Leu), which confer resistance to DPP-IV cleavage and other degradation pathways, extending the biological half-life from less than 7 minutes (native GHRH) to approximately 30 minutes. Consequently, this binding activates a downstream signaling cascade that results in GH synthesis and release.<\/p>\n

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH\u2082. It mimics ghrelin and binds to the ghrelin receptor (GHS-R1a) in the pituitary, thereby selectively stimulating the release of GH. Unlike other GH releasing peptides, Ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone, with negligible cortisol or prolactin elevation. This selectivity makes Ipamorelin a valuable tool for researchers seeking isolated GH effects without the confounding influences of adrenal axis activation. Ipamorelin has a molecular weight of 711.85 g\/mol, the molecular formula C\u2083\u2088H\u2084\u2089N\u2089O\u2085, and a CAS number of 170851-70-4.<\/p>\n

When combined, Mod GRF 1-29 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release with minimal cortisol or prolactin elevation. As a result, this dual combination amplifies GH output through convergent but mechanistically independent pathways. Accordingly, researchers who buy Mod GRF 1-29 & Ipamorelin Blend in Switzerland from Core Peptides can support their investigations into GH axis signaling, synergistic peptide interactions, and selective GH release mechanisms.<\/p>\n

How Does the Mod GRF 1-29 & Ipamorelin Blend Work in Research?<\/strong><\/h2>\n

Mechanistically, the Mod GRF 1-29 and Ipamorelin blend operates through two complementary signaling pathways that converge on GH release from pituitary somatotrophs.<\/p>\n

GHRH Receptor Pathway (Mod GRF 1-29)<\/strong><\/h3>\n

Mod GRF 1-29 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. It functions as a stable and active hGRF1-29 analog with a half-life of approximately 30 minutes. The amino acid substitutions at positions 2, 8, 15, and 27 confer resistance to DPP-IV cleavage, extending the effective half-life compared to native GHRH. Consequently, this binding initiates a downstream signaling cascade that results in GH synthesis and release.<\/p>\n

GHS-R1a Pathway (Ipamorelin)<\/strong><\/h3>\n

Ipamorelin binds the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor, through Gq\/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. Notably, Ipamorelin’s key distinguishing feature is its failure to significantly stimulate ACTH or cortisol release at GH-effective doses, suggesting preferential activation of specific downstream signaling branches. As a result, Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation, making it valuable for studies requiring isolated GH effects.<\/p>\n

Synergistic Effects<\/strong><\/h3>\n

The dual combination produces synergistic (not merely additive) GH release. Specifically, Mod GRF 1-29 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release. Ipamorelin works by activating GHS-R1a receptors on pituitary cells, triggering one specific signaling pathway (Gq\/Gi G-protein coupled). At the same time, Mod GRF 1-29 works by activating GHRH receptors on the same pituitary cells, triggering a different signaling pathway (Gs G-protein coupled). When both pathways are activated simultaneously, the result is multiplicative\u2014far greater than either pathway alone. Furthermore, Ipamorelin’s selective GH release profile with minimal cortisol elevation makes this blend a preferred choice for researchers seeking isolated GH effects without adrenal axis activation.<\/p>\n

Why Is the Mod GRF 1-29 & Ipamorelin Blend Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study this blend because it represents a well-characterized dual combination of complementary GH secretagogues that enables investigation of synergistic GH release, metabolic regulation, and selective receptor pharmacology. In fact, this pre-mixed blend offers a practical way to study convergent GH axis signaling without the need to source and reconstitute each compound separately.<\/p>\n

Research has demonstrated the blend’s relevance across multiple domains. For instance, GH pulse amplitude is a key determinant of recovery-relevant downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Furthermore, research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity, supporting the value of high-amplitude pulse protocols. Additionally, Ipamorelin’s selective GH release profile with minimal cortisol elevation makes it valuable for studies requiring isolated GH effects without the confounding influences of adrenal axis activation. Ultimately, researchers who buy Mod GRF 1-29 & Ipamorelin Blend in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, metabolic regulation, and selective receptor pharmacology.<\/p>\n

Mod GRF 1-29 & Ipamorelin Blend Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nKey Components<\/th>\n<\/tr>\n<\/thead>\n
GH Axis Signaling<\/td>\nDual-pathway activation, GHRH\/GHS receptor crosstalk, pulsatile secretion<\/td>\nBoth (complementary pathways)<\/td>\n<\/tr>\n
Selective GH Release<\/td>\nGH-specific effects, minimal cortisol\/prolactin spillover, adrenal sparing<\/td>\nIpamorelin<\/td>\n<\/tr>\n
Metabolic Regulation<\/td>\nIGF-1 elevation, lipolysis, protein synthesis, metabolic homeostasis<\/td>\nBoth (GH-dependent effects)<\/td>\n<\/tr>\n
Receptor Pharmacology<\/td>\nGHRH-R, GHS-R1a binding, biased agonism, receptor binding kinetics<\/td>\nBoth (distinct targets)<\/td>\n<\/tr>\n
Pulsatile GH Secretion<\/td>\nPhysiologic GH patterning, amplitude modulation, pulse dynamics<\/td>\nMod GRF 1-29<\/td>\n<\/tr>\n
Endocrine Research<\/td>\nHormone profiling, cortisol\/prolactin studies, adrenal axis sparing<\/td>\nBoth<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Mod GRF 1-29 & Ipamorelin Blend Compared With Related Research Formulations<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Formulation<\/th>\nComponents<\/th>\nResearch Focus<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
Mod GRF 1-29 + Ipamorelin Blend<\/td>\nMod GRF 1-29 + Ipamorelin (1:1)<\/td>\nGH axis, selective GH release, metabolic regulation<\/td>\nWeaker GH pulse; minimal cortisol\/prolactin spillover<\/td>\n<\/tr>\n
Mod GRF 1-29 + GHRP-2 Blend<\/td>\nMod GRF 1-29 + GHRP-2<\/td>\nGH axis, synergistic release, metabolic regulation<\/td>\nStronger GH release, more cortisol\/prolactin elevation<\/td>\n<\/tr>\n
Mod GRF 1-29 + GHRP-6 Blend<\/td>\nMod GRF 1-29 + GHRP-6<\/td>\nGH axis, synergistic release, appetite modulation<\/td>\nSignificant appetite stimulation via GHRP-6<\/td>\n<\/tr>\n
Mod GRF 1-29 + Hexarelin Blend<\/td>\nMod GRF 1-29 + Hexarelin<\/td>\nGH axis, cardioprotection<\/td>\nHexarelin adds CD36 cardioprotection<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, the Mod GRF 1-29 and Ipamorelin blend differs from other GHRH\/GHS combinations in its selectivity. On the one hand, Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation. On the other hand, other GHRPs such as GHRP-2, GHRP-6, and Hexarelin generate robust GH output alongside measurable increases in ACTH, cortisol, and prolactin. In contrast, the Mod GRF 1-29 and Ipamorelin blend is frequently chosen for its favorable selectivity profile, making it suitable for research applications requiring isolated GH effects without adrenal axis activation.<\/p>\n

Research Applications for the Mod GRF 1-29 & Ipamorelin Blend in Switzerland<\/strong><\/h2>\n

Scientists have investigated this peptide blend across several research domains:<\/p>\n